OpenExamsFREE PRACTICE — ANY EXAM

Wyoming Pharmacist — Requirements & Free Practice

US-WY · License preparation

721 free questions · Answer explanations · No signup required

Choose what to practice

Start with an exam below. Your examination requirements depend on your application pathway. View licensing requirements

Combined practice

Choose an exam or combined practice to begin.

Licenses, application pathways and examination requirements

Each license and applicant pathway has its own requirements and exemptions. Choosing practice questions does not determine your eligibility.

Pharmacist License

License to practice pharmacy in Wyoming issued by the Wyoming State Board of Pharmacy under the Wyoming Pharmacy Act (W.S. 33-24-101 et seq.) and Board Rules Chapter 19.

Licensing authority: Wyoming State Board of Pharmacy · Application information

Licensure by examination
Age
Has attained the age of majority (W.S. 33-24-116(a)(ii)).
Application
Completed Wyoming Application for Pharmacist Licensure by Examination/Score Transfer with the application fee (W.S. 33-24-116(a)(i), (vii); Rules Ch. 19 Sec. 5(b)(i)).
Background
Background that does not evidence conduct adverse to the practice of pharmacy (W.S. 33-24-116(a)(iii)); fingerprints and fees for a criminal history record check, and the Board must receive the Wyoming DCI criminal background history report before licensure (W.S. 33-24-116(a)(viii); Rules Ch. 19 Sec. 5(b)(i), (vii)).
Education
Professional degree (BS in Pharmacy or PharmD) from a Board-approved, ACPE-accredited college or school of pharmacy (W.S. 33-24-116(a)(iv); application instructions item 1.b.i).
Internship
1,200 hours of Board-approved internship/practical experience (W.S. 33-24-116(a)(v), 33-24-135; Rules Ch. 19 Sec. 5(b)(iv), 5(d)).
Interview
The Board may require an interview (Rules Ch. 19 Sec. 5(f)).
Naplex Score Transfer
The NAPLEX may be taken for Wyoming or its score transferred to Wyoming; a transferred NAPLEX score must be 75 or more and all requirements must be completed within one year of the NAPLEX examination date used for the transfer, otherwise the applicant must seek licensure by license transfer (Rules Ch. 19 Sec. 5(c), 5(e); application instructions item 3.b).
Passing Scores
NAPLEX with a minimum score of 75 (up to three attempts) and the MPJE for Wyoming with a minimum score of 75 (up to five attempts) (Rules Ch. 19 Sec. 5(b)(ii)-(iii)).
Time Limit
By examination (without score transfer), all requirements must be completed within two years of the date of application (Rules Ch. 19 Sec. 5(b)(v)).
Licensure by examination foreign pharmacy graduate
Age
Has attained the age of majority (W.S. 33-24-116(a)(ii)).
Application
Completed Wyoming Application for Pharmacist Licensure by Examination/Score Transfer with the application fee (W.S. 33-24-116(a)(i), (vii); Rules Ch. 19 Sec. 5(b)(i)).
Background
Background that does not evidence conduct adverse to the practice of pharmacy (W.S. 33-24-116(a)(iii)); fingerprints and fees for a criminal history record check, and the Board must receive the Wyoming DCI criminal background history report before licensure (W.S. 33-24-116(a)(viii); Rules Ch. 19 Sec. 5(b)(i), (vii)).
Foreign Graduate
Applies to foreign pharmacy graduates: pharmacy degree conferred by a recognized school outside the United States, the District of Columbia and Puerto Rico (Rules Ch. 19 Sec. 4(a)).
Fpgec Certificate
Must hold a validated FPGEC Certificate issued by the Foreign Pharmacy Graduate Examination Committee, which requires verification of educational equivalency and foreign licensure/registration, a passing FPGEE score, and TOEFL iBT scores of at least 21 listening, 22 reading, 26 speaking and 24 writing (W.S. 33-24-116(a)(iv); Rules Ch. 19 Sec. 5(h)).
Internship
1,200 hours of Board-approved internship/practical experience (W.S. 33-24-116(a)(v), 33-24-135; Rules Ch. 19 Sec. 5(b)(iv), 5(d)).
Interview
The Board may require an interview (Rules Ch. 19 Sec. 5(f)).
Naplex Score Transfer
The NAPLEX may be taken for Wyoming or its score transferred to Wyoming; a transferred NAPLEX score must be 75 or more and all requirements must be completed within one year of the NAPLEX examination date used for the transfer, otherwise the applicant must seek licensure by license transfer (Rules Ch. 19 Sec. 5(c), 5(e); application instructions item 3.b).
Passing Scores
NAPLEX with a minimum score of 75 (up to three attempts) and the MPJE for Wyoming with a minimum score of 75 (up to five attempts) (Rules Ch. 19 Sec. 5(b)(ii)-(iii)).
Time Limit
By examination (without score transfer), all requirements must be completed within two years of the date of application (Rules Ch. 19 Sec. 5(b)(v)).
Licensure by reciprocal license transfer
multistate pharmacy jurisprudence examination (mpje®)
Application
Wyoming Application for Pharmacist Licensure by Reciprocity/License Transfer with the $200 license transfer fee and $50 background check fee, fingerprint cards, verification of active practice and a notarized character affidavit (W.S. 33-24-134(a)(i), (vi)-(vii); Rules Ch. 19 Sec. 6(a)(i); license transfer packet).
Board Discretion
Licensure by reciprocity is in the Board's sole discretion and the Board may require an interview (W.S. 33-24-134(a); Rules Ch. 19 Sec. 6(a)(v)).
Education
Graduate of an ACPE-accredited college/school of pharmacy and meets W.S. 33-24-116(a)(ii) through (iv) (W.S. 33-24-134(a)(ii); license transfer packet).
Good Moral Character
Proof of good moral character (Rules Ch. 19 Sec. 6(a)(i)(F)).
License Elsewhere
Licensed as a pharmacist by examination and in good standing in another state that is a member of NABP; any other state license not suspended, revoked or restricted except for nonrenewal or missing continuing education (W.S. 33-24-134(a)(iv)-(v); Rules Ch. 19 Sec. 6(a)).
Mpje Attempts
The MPJE for Wyoming allows a total of five attempts with a 30-day wait after a failed attempt (license transfer packet).
Nabp Transfer
NABP Electronic License Transfer (Preliminary Application for Transfer of Pharmacist Licensure) application and fees; the transfer application expires one year from its NABP issue date (Rules Ch. 19 Sec. 6(a), 6(a)(i)(iv); license transfer packet).
Practice Experience
Active pharmacy practice in the year preceding the application, or a Board-approved Wyoming internship of at least 400 hours (W.S. 33-24-134(a)(iii); Rules Ch. 19 Sec. 6(a)(i)(G)).
Licensure by reciprocal license transfer foreign pharmacy graduate
Application
Wyoming license transfer application with fees, fingerprints, verification of active practice, notarized character affidavit and a copy of the FPGEC Certificate (license transfer packet).
Board Discretion
Licensure by reciprocity is in the Board's sole discretion and the Board may require an interview (W.S. 33-24-134(a); Rules Ch. 19 Sec. 6(a)(v)).
Foreign Graduate
Applies to a foreign pharmacy graduate applying by license transfer, who must possess a validated FPGEC Certificate (whose requirements include a passing FPGEE score and TOEFL iBT scores) (W.S. 33-24-134(a)(ii), 33-24-116(a)(iv); Rules Ch. 19 Sec. 5(h), 6(a)(i)(I); license transfer packet).
License Elsewhere
Licensed as a pharmacist by examination and in good standing in another NABP member state (W.S. 33-24-134(a)(iv)-(v); Rules Ch. 19 Sec. 6(a)).
Nabp Transfer
NABP Electronic License Transfer application and fees; expires one year from its NABP issue date (Rules Ch. 19 Sec. 6(a)(iv)).
Practice Experience
Active pharmacy practice in the year preceding the application, or a Board-approved Wyoming internship of at least 400 hours (Rules Ch. 19 Sec. 6(a)(i)(G)).
Reinstatement of lapsed license
No examination is required for this applicant pathway.
Eligibility
License lapsed only for failure to renew/pay renewal fees (Rules Ch. 19 Sec. 7(a); reinstatement application purpose).
Requirements
Letter requesting reinstatement; back renewal fees and annual fines up to five years; CE certificates for the lapsed years up to five years; two recent character letters from a pharmacist; letter from the board of the state where currently licensed, if licensed outside Wyoming; fingerprints with $50 fee; notarized employer affidavit of at least 400 hours of active practice in the preceding year (Rules Ch. 19 Sec. 7(a)(i)-(vii)).

Official no-examination sources

Effective from 2018-12-19.

Annual renewal and restoration
No examination is required for this applicant pathway.
Continuing Education
15 hours of approved continuing pharmaceutical education per license period, including 1.5 hours on responsible prescribing of controlled substances; exempt for the first renewal period (W.S. 33-24-121(d); Rules Ch. 6 Sec. 3).
Renewal
Renew on or before December 31 each year with signature, registration number, address, annual fee and criminal, substance abuse, professional liability and licensure history information (W.S. 33-24-121(a)).
Restoration
An expired license may be restored upon compliance with the renewal requirements not later than March 31 following expiration; afterwards reinstatement is required (W.S. 33-24-121(c); Board pharmacist page).

Official no-examination sources

Effective from 2023-08-31.

Temporary Pharmacist License

Non-renewable temporary pharmacist license valid for up to six months, available to license transfer applicants under W.S. 33-24-134(e).

Licensing authority: Wyoming State Board of Pharmacy · Application information

Temporary license pending license transfer
No examination is required for this applicant pathway.
Duration
Valid for no more than six months from issuance and not renewable (W.S. 33-24-134(e)).
Requirements
Applicant has met W.S. 33-24-134(a)(i) through (vii) and other Board requirements: a completed NABP Electronic License Transfer application, a completed Wyoming Pharmacist Application for Licensure by Reciprocity/License Transfer and a $25 temporary license fee; the Board may delay issuance pending the background check (W.S. 33-24-134(e); license transfer packet).

Official no-examination sources

Effective from 2026-08-30.

Foreign Pharmacy Graduate Equivalency Examination

Provider
National Association of Boards of Pharmacy
Format
Computerized fixed form
Exam questions
200 questions
Time limit
4.5 hours examination time; 5.5 hours total seat time
Passing score
Scaled score of 75
Examination outline
  • Foundational Biomedical Sciences (12%)
    • Anatomy and physiology
    • Biochemistry
    • Medical microbiology
    • Immunology
    • Pathophysiological bases of diseases
  • Pharmaceutical Sciences (31%)
    • Pharmaceutical calculations (eg, dose adjustments, delivery, ionization, ionic strength, isotonicity, ratio/percentage strength, osmolarity)
    • Medicinal chemistry
    • Medicinal chemistry: Physicochemical properties of drugs in relation to drug absorption, distribution, metabolism, and excretion (ADME)
    • Medicinal chemistry: Pathways of drug metabolism
    • Medicinal chemistry: Chemical bases for drug action, including bioorganic chemistry, structure-activity relationships, and fundamental pharmacophores related to drug-receptor interactions
    • Medicinal chemistry: Applicability to making drug therapy decisions
    • Pharmacology and toxicology
    • Pharmacology and toxicology: Pharmacodynamics, including drug-receptor interactions, agonists, antagonists, inverse agonists, and dose-response curves
    • Pharmacology and toxicology: Mechanisms of action of drugs, including biologics
    • Pharmacology and toxicology: Adverse effects and side effects of drugs
    • Pharmacology and toxicology: Mechanisms of drug interactions, including drug-drug, drug-disease, drug-food, drug-allergy, and drug-laboratory interactions
    • Pharmacology and toxicology: Mechanisms of acute and chronic toxic effects of xenobiotics, including drug and chemical overdose or exposure and antidotes
    • Pharmaceutics and biopharmaceutics
    • Pharmaceutics and biopharmaceutics: Dosage form development and drug delivery systems such as immediate release, sustained release, and controlled release
    • Pharmaceutics and biopharmaceutics: Disintegration and dissolution of solid oral dosage forms
    • Pharmaceutics and biopharmaceutics: Physicochemical properties of drugs, excipients, solutions, and dosage forms
    • Pharmaceutics and biopharmaceutics: Physical stability, chemical stability, and shelf-lives, including zero-, first-, second-, and pseudo-order reactions
    • Pharmaceutics and biopharmaceutics: Interactions between drug formulation and biological effects
    • Pharmaceutics and biopharmaceutics: Drug product manufacturing, including methods, processing, and quality assurance
    • Pharmacokinetics
    • Pharmacokinetics: Determining rates of absorption, distribution, metabolism, and excretion (ADME) of drugs
    • Pharmacokinetics: Factors affecting rates of ADME, including age, sex, genetics, diet, disease, and drug interactions
    • Pharmacokinetics: Biological half-lives of drugs and related dosing
    • Pharmacokinetics: Compartment models (one-, two-, and non-)
    • Pharmacokinetics: Linear and nonlinear pharmacokinetics
    • Pharmacokinetics: Principles of bioavailability, bioequivalence, and biosimilars
    • Pharmacogenomics (eg, population-based genetic influences on drug metabolism and efficacy, genetic testing, tumor genotyping, pharmacogenetic screening)
    • Extemporaneous compounding (eg, United States Pharmacopeia (USP) standards including Chapters <795>, <797>, and <800>; dosage form preparation calculations; techniques used to prepare and dispense sterile and nonsterile preparations)
  • Social, Behavioral, and Administrative Sciences (20%)
    • Pharmacy law and ethics
    • Pharmacy law and ethics: Laws and regulations governing pharmacy
    • Pharmacy law and ethics: Regulatory, oversight, and professional organizations
    • Pharmacy law and ethics: Principles and application of biomedical ethics
    • Health care systems
    • Health care systems: Organization, regulation, and financing of health care delivery in the United States
    • Health care systems: Factors that influence delivery and use of health care (eg, social, political, economic, and technological)
    • Pharmacoeconomics (eg, analysis, interpretation, application, humanistic outcomes)
    • Population-based care, pharmacoepidemiology, and public health
    • Population-based care, pharmacoepidemiology, and public health: Data sources and analytic tools
    • Population-based care, pharmacoepidemiology, and public health: Application of epidemiological study design
    • Population-based care, pharmacoepidemiology, and public health: Health promotion, disease prevention, and infection control
    • Population-based care, pharmacoepidemiology, and public health: Continuous quality improvement
    • Population-based care, pharmacoepidemiology, and public health: Social determinants and drivers of health
    • Practice management
    • Practice management: Financial management and budgeting
    • Practice management: Personnel management
    • Practice management: Business and strategic planning
    • Practice management: Risk management
    • Practice management: Procurement and inventory control
    • Professional communication
    • Professional communication: Verbal, nonverbal, written, and technology-based communication with patients, caregivers, providers, and stakeholders
    • Professional communication: Health literacy
    • Biostatistics and research methods (eg, study design, statistical tests, data collection instruments, research ethics)
    • Social and behavioral aspects of practice
    • Social and behavioral aspects of practice: Patient behavior including health-, illness-, and sick-role
    • Social and behavioral aspects of practice: Principles of behavior modification
    • Social and behavioral aspects of practice: Patient adherence
    • Social and behavioral aspects of practice: Cultural awareness
  • Pharmacy Practice and Clinical Sciences (37%)
    • Clinical pathophysiology as it applies to treatment of disease processes
    • Data collection (eg, patient history, physical assessments, laboratory values, point-of-care testing)
    • Data assessment (eg, clinical calculations, interpretation of data, diagnosing)
    • Patient-care decision making, therapy recommendations, and education (eg, plan, implement, monitor, follow-up)
    • Patient safety (eg, drug interactions, toxicity, drug-induced disease, drug use disorders)
    • Disease prevention (eg, screenings, immunization, non-pharmacological therapies, lifestyle modifications)
    • Personalized medicine (eg, pharmacokinetics, pharmacogenetics)
    • Evidence-based practice
    • Evidence-based practice: Practice guidelines
    • Evidence-based practice: Drug information and evaluation
    • Evidence-based practice: Information source reliability
    • Evidence-based practice: Clinical trial evaluation
    • Self-care, including using natural products
Examination sources

North American Pharmacist Licensure Examination

Provider
National Association of Boards of Pharmacy
Format
Computerized fixed form
Exam questions
225 questions
Time limit
6 hours
Passing score
Pass or Fail
Examination outline
  • Foundational Knowledge for Pharmacy Practice (25%)
    • Pharmaceutical science principles and concepts
    • Pharmaceutical science principles and concepts: Pharmacology
    • Pharmaceutical science principles and concepts: Pharmacokinetics, pharmacodynamics, or pharmacogenomics
    • Pharmaceutical science principles and concepts: Pharmaceutics
    • Pharmaceutical compounding
    • Pharmaceutical compounding: Nonsterile preparations
    • Pharmaceutical compounding: Sterile preparations
    • Pharmaceutical calculations
    • Pharmaceutical calculations: Patient parameters or laboratory measures
    • Pharmaceutical calculations: Quantities of drugs to be dispensed or administered
    • Pharmaceutical calculations: Rates of administration
    • Pharmaceutical calculations: Dose conversions
    • Pharmaceutical calculations: Drug concentrations, ratio strengths, osmolarity, or osmolality
    • Pharmaceutical calculations: Quantities of drugs or ingredients to be compounded
    • Pharmaceutical calculations: Nutritional needs and the content of nutrient sources
    • Pharmaceutical calculations: Biostatistical, epidemiological, or pharmacoeconomic measures
    • Pharmaceutical calculations: Pharmacokinetic parameters
    • Drug development processes (eg, clinical trial phases, emergency use authorizations)
    • Research design principles and biostatistics (eg, blinding, randomization, biases, statistical tests and outcomes, ethics)
    • Retrieval, assessment, and interpretation of primary, secondary, and tertiary resources
  • Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring) (25%)
    • Prescriptions and medication order interpretation
    • Prescriptions and medication order interpretation: Drug names and therapeutic classes
    • Prescriptions and medication order interpretation: Indications, usage, and dosing regimens
    • Prescriptions and medication order interpretation: Available dosage forms
    • Prescriptions and medication order interpretation: Prescription regulations (eg, boxed warnings, risk evaluation and mitigation strategies)
    • Prescriptions and medication order interpretation: Safety and effectiveness (eg, laboratory parameters, vital signs)
    • Therapeutic substitutions (eg, formulary restrictions, therapeutic alternatives, shortages, biosimilars)
    • Immunization services and documentation
    • Immunization services and documentation: Indications and scheduling
    • Immunization services and documentation: Contraindications and precautions
    • Immunization services and documentation: Storage and handling
    • Immunization services and documentation: Administration (eg, techniques, preparation, routes)
    • Immunization services and documentation: Adverse reactions
    • Medication handling, storage, stability, and disposal (eg, hazardous and nonhazardous drugs, controlled substances, parenteral medications, sharps handling, temperature control)
  • Person-Centered Assessment and Treatment Planning (40%)
    • Medication history, allergy history, and reconciliation
    • Health histories, screenings, and assessments
    • Patient health conditions, including special populations and medication-related factors
    • Patient health conditions, including special populations and medication-related factors: Signs, symptoms, and findings of medical conditions, etiology of diseases, or pathophysiology
    • Patient health conditions, including special populations and medication-related factors: Appropriateness of therapy (eg, medications, immunizations, non-drug therapy, dosing, contraindications, warnings, evidence-based decision making)
    • Patient health conditions, including special populations and medication-related factors: Interactions (eg, drug-drug, drug-condition, drug-food, drug-allergy, drug-laboratory)
    • Patient health conditions, including special populations and medication-related factors: Errors and omissions (eg, dosing, duplication, additional therapy needed, unnecessary therapy)
    • Patient health conditions, including special populations and medication-related factors: Adverse drug reactions
    • Patient health conditions, including special populations and medication-related factors: Toxicologic exposures and overdoses
    • Patient health conditions, including special populations and medication-related factors: Adherence
    • Therapeutic monitoring, plan development, evaluation, and modifications
    • Therapeutic monitoring, plan development, evaluation, and modifications: Therapeutic goals, clinical endpoints, and follow-up
    • Therapeutic monitoring, plan development, evaluation, and modifications: Safety
    • Therapeutic monitoring, plan development, evaluation, and modifications: Effectiveness
    • Patient education
    • Patient education: Lifestyle modifications and health maintenance
    • Patient education: Medication use, storage, and disposal
    • Patient education: Disease state management
    • Over-the-counter medications and dietary supplements
    • Devices to administer medications and self-monitoring tests
  • Professional Practice (5%)
    • Adverse drug event reporting and medication error reporting (eg, MedWatch, VAERS)
    • Public health initiatives and risk-prevention programs (eg, tobacco and nicotine cessation, antimicrobial stewardship, health screenings, opioid stewardship)
    • Social determinants and drivers of health
    • Ethical considerations (eg, informed consent, ethical principles, professional conduct and responsibility, patient confidentiality)
  • Pharmacy Management and Leadership (5%)
    • Pharmacy operations (eg, operational planning, risk management, regulations and regulatory bodies, technology applications and informatics, error-prevention strategies, medication safety)
    • Inventory and supply management (eg, drug recalls, drug shortages)
    • Quality improvement activities (eg, medication use evaluation, root-cause analysis, continuous quality improvement)
    • Mentorship and preceptorship (eg, providing and receiving feedback, delegation of work activities, preceptor roles)
Examination sources

multistate pharmacy jurisprudence examination (mpje®)

Provider
National Association of Boards of Pharmacy (NABP); delivered at Pearson VUE test centers
Format
Computer adaptive test; selected-response items (multiple choice and multiple response)
Exam questions
120
Time limit
2.5 hours
Passing score
Minimum score of 75 (Wyoming Board Rules Ch. 19); reported as pass or fail
Examination outline
  • Area 1 — Licensure/Personnel (22%)
    • Responsibilities of the pharmacist and non-pharmacist personnel
    • Qualifications, scope of duties, limitations, and restrictions of duties, or conditions to practice for pharmacists-in-charge (or equivalent) and pharmacists
    • Qualifications, scope of duties, limitations, and restrictions of duties, or conditions to practice for non-pharmacist personnel
    • Licensures, registrations, and certifications for pharmacists or non-pharmacist personnel
    • Qualifications, examinations, internships, maintaining pharmacist competency, and renewals of licensures, registrations, or certifications
    • Classifications and processes of disciplinary actions
    • Reporting to and participating in programs addressing the inability to practice with reasonable skill and safety
  • Area 2 — Pharmacist Practice (33%)
    • Requirements for issuing prescriptions/drug orders
    • Requirements for drug uses, limitations, or restrictions
    • Scope of authority, scope of practice, limitations or restrictions of practice, and valid registration of practitioners who are authorized to prescribe, dispense, or administer drugs
    • Requirements for issuing non-controlled prescriptions/drug orders
    • Requirements for issuing controlled prescriptions/drug orders
    • Authority limitations of practitioners’ ability to authorize refills
    • Conditions under which the pharmacist or non-pharmacist personnel participates in the administration of drugs in the management of patients’ therapy
    • Requirements regarding counseling
    • Counseling or offering to counsel
    • Documenting counseling or documenting offering to counsel
    • Returning or reusing drugs
    • Regulations and agencies regarding pharmacy practice
    • Requirements for promoting quality and safety of public health
    • Protecting patient and health record confidentiality
  • Area 3 — Dispensing Requirements (24%)
    • Responsibilities for determining whether prescriptions/drug orders are issued for a legitimate medical purpose, and within all applicable restrictions
    • Transferring prescription/drug order information between pharmacies by authorized personnel
    • Prospective drug utilization reviews
    • Requirements for reporting to PMP and accessing PMP data
    • Exceptions to dispensing or refilling prescriptions/drug orders
    • Labeling of dispensed drugs
    • Packaging of dispensed drugs
    • Drug product conditions prohibiting dispensing
    • Requirements for the distribution and/or dispensing of non-prescription pharmaceutical products, including controlled substances and hazardous drugs
    • Dispensing or administration
    • Labeling of non-prescription drugs and devices
    • Packaging and repackaging of non-prescription drugs and behind-the-counter products
    • Dispensing-restricted, non-prescription drugs
  • Area 4 — Pharmacy Operations (21%)
    • Ordering, acquisition, and distribution of drugs, including maintenance and content of such records
    • Ordering and acquisition, including the maintenance and content of such records
    • Distribution, including the maintenance and content of such records
    • Recordkeeping in compliance with legal requirements, including content, inventory, maintenance, storage, handling, and reporting
    • Non-dispensing requirements for operations of pharmacies or practice settings
    • Possession, storage, and handling of non-hazardous drugs
    • Training, possession, handling, storage, and disposal of hazardous drugs
    • Allowing non-pharmacist personnel access to drugs
    • Requirements for conducting controlled substance inventories
    • Delivery of drugs
    • Conditions for permitted or mandated product selection
    • Compounding sterile, nonsterile, hazardous, and non-hazardous preparations
    • Centralized prescription processing or central-fill pharmacy dispensing
    • Requirements for the registration, licensure, certification, or permitting of a practice setting or business entity
    • Requirements for registration, license, certification, or permitting of a practice setting
    • Requirements for the renewal or reinstatement of a license, registration, certificate, or permit of a practice setting
    • Requirements for an inspection of a licensed, registered, certified, or permitted practice setting
    • Classifications and processes of disciplinary actions that may be taken against a registered, licensed, certified, or permitted practice setting
Examination sources